8-K: GRAIL Q2 2025: Galleri Revenue Up 22%, Net Loss Narrows

GRAIL, Inc. reported a 22% year-over-year increase in Galleri revenue to $34.4 million and a significant 93% reduction in net loss for the second quarter of 2025, alongside positive clinical trial results.

Summary

• Total revenue for the second quarter of 2025 increased 11% year-over-year to $35.5 million.
• Galleri revenue grew 22% year-over-year to $34.4 million, with U.S. Galleri revenue reaching $34.2 million, a 21% year-over-year increase.
• More than 45,000 Galleri tests were sold in the second quarter, representing a 29% year-over-year growth.
• Net loss for the quarter was $114.0 million, a 93% improvement compared to a net loss of $1,585.337 million in the second quarter of 2024.
• The net loss includes an impairment of Illumina acquisition-related intangible assets of $28.0 million, significantly lower than the $1.42 billion impairment in Q2 2024.
• Adjusted gross profit was $16.1 million, a 1% increase year-over-year.
• Adjusted EBITDA improved by 44% year-over-year to $(78.3) million.
• Cash, cash equivalents, restricted cash, and short-term marketable securities totaled $606.1 million as of June 30, 2025.
• Positive top-line performance and safety results were announced in June from the PATHFINDER 2 study, showing substantially greater additional cancer detection and higher positive predictive value (PPV) compared to the first PATHFINDER study.
• The prevalent screening round of the NHS-Galleri trial also showed a substantially higher PPV, with consistent cancer signal origin (CSO) accuracy and specificity.
• A new collaboration with Everlywell was established to expand access to the Galleri test, making it available for direct request via prescription on everlywell.com.
• Rush University System for Health became the first health system in the Chicago-area market to offer the Galleri test in July.
• Five-year follow-up analysis data from the Circulating Cell-free Genome Atlas (CCGA) study, presented at ASCO in May, demonstrated Galleri's preferential detection of aggressive, clinically meaningful cancers.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant improvements in key financial metrics, particularly the substantial reduction in net loss and improved adjusted EBITDA. Strong growth in Galleri revenue and test sales, coupled with positive clinical trial results and expanded market access initiatives, indicate strong operational momentum and future potential.

Positives

• Significant 93% year-over-year improvement in net loss, reducing it to $114.0 million.
• Strong growth in Galleri revenue, up 22% year-over-year to $34.4 million, indicating increasing market adoption.
• U.S. Galleri revenue specifically grew 21% year-over-year to $34.2 million.
• Galleri tests sold increased by 29% year-over-year to over 45,000, demonstrating strong product uptake.
• Adjusted EBITDA improved by 44% year-over-year to $(78.3) million, reflecting better operational efficiency.
• Positive top-line results from the registrational PATHFINDER 2 study showed substantially greater additional cancer detection and higher positive predictive value.
• Positive top-line results from the NHS-Galleri trial indicated a substantially higher positive predictive value.
• Expanded market access through a new collaboration with Everlywell, making Galleri available directly online via prescription.
• Adoption by a major health system, Rush University System for Health, signals growing clinical acceptance.
• Clinical data presented at ASCO reinforced Galleri's ability to detect aggressive, clinically meaningful cancers.

Negatives

• The company continues to report a net loss of $114.0 million for the quarter.
• Gross loss was $17.8 million, indicating that direct costs still exceed revenue.
• An impairment charge of $28.0 million related to Illumina acquisition-related intangible assets was recorded in the quarter.

Risks

• The company recorded an impairment of Illumina acquisition-related intangible assets of $28.0 million, indicating potential challenges with asset valuation or integration from past transactions.
• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the company's control, including those discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, and the Quarterly Report on Form 10-Q for the period ended June 30, 2025.

Future Outlook

The company anticipates continued growing uptake of Galleri in the U.S. by driving provider and patient awareness. Registrational trials in the U.S. and U.K. are beginning to read out, with detailed results from the PATHFINDER 2 study planned for submission for presentation at the European Society for Medical Oncology Congress 2025 in October.

Management Comments

• "We are pleased with Galleri's growing uptake in the U.S., with more than 45,000 Galleri tests sold in the second quarter, as we continue to drive provider and patient awareness of the MCED opportunity and Galleri's ability to detect cancer earlier, when it is more amenable to treatment."
• "Our registrational trials in large, intended use populations in the U.S. and U.K. are beginning to read out, and following very promising top-line performance and safety results from the PATHFINDER 2 study in the U.S., we plan to submit detailed results for presentation at the European Society for Medical Oncology Congress 2025 in October."

Industry Context

The announcement highlights GRAIL's continued progress in the multi-cancer early detection (MCED) market, a rapidly evolving segment within diagnostics and oncology. The growing adoption of Galleri, evidenced by increased test sales and new collaborations with digital health platforms like Everlywell and major health systems such as Rush University System for Health, indicates a strategic push to expand market reach and integrate MCED into standard care pathways. Positive clinical trial readouts from PATHFINDER 2 and NHS-Galleri trials reinforce the scientific validation crucial for broader acceptance and potential regulatory approvals in the competitive diagnostics landscape.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company incurred legal and professional services costs related to the Illumina acquisition and corresponding antitrust litigation, including compliance with hold separate arrangements imposed by the European Commission, and costs associated with its divestiture from Illumina.

Stakeholder Impact

• Shareholders are positively impacted by the significant reduction in net loss, improved adjusted EBITDA, and strong revenue growth for the core product, Galleri.
• Patients may benefit from expanded access to the Galleri test through new collaborations like Everlywell and adoption by major health systems, potentially leading to earlier cancer detection.
• Healthcare providers gain a validated tool for multi-cancer early detection, supported by positive clinical trial data, enhancing their ability to offer proactive cancer screening.

Next Steps

• Submit detailed results from the PATHFINDER 2 study for presentation at the European Society for Medical Oncology Congress (ESMO) 2025 in October.

Key Dates

Recommendation

The company demonstrated substantial financial improvement, notably a 93% reduction in net loss and a 44% improvement in Adjusted EBITDA. Galleri revenue and test sales showed robust growth, indicating strong market adoption for its flagship product. Positive clinical trial results from PATHFINDER 2 and NHS-Galleri trials provide strong validation for the technology, and strategic partnerships are expanding market access. These factors collectively suggest a positive trajectory and strong potential for future growth and profitability, making it an attractive investment.

Keywords

GRAIL, Galleri, cancer detection, multi-cancer early detection, MCED, oncology, diagnostics, biotechnology, healthcare, financial results, earnings, clinical trials, PATHFINDER, NHS-Galleri, ASCO